Maternal Health Market Size and Investment Trends

Ask ten analysts how big the maternal health market is and you'll get ten different answers, sometimes off by a factor of twenty. Nobody's bad at math here, though. "Maternal health market" just means at least three different things depending on who's counting, and most coverage never says which one it means.

Start with the tightest definition, the one that shows up when a research firm says "maternal health market" with no qualifiers attached. This scope covers drugs, prenatal supplements, monitoring devices, and direct maternal therapeutics. It leaves out hospital services and pediatric care entirely, and that matters, because those two categories are exactly what balloon every other estimate later in this piece.

Even inside this narrow lane, the numbers can't agree with each other. Market Research Future puts the 2025 figure at USD 31.31 billion, climbing to USD 140.20 billion by 2035 at a 14.60% compound annual growth rate. Maximize Market Research, working off a more conservative model, has 2024 at USD 17.49 billion, reaching just USD 32.92 billion by 2032, an 8.22% CAGR. Business Research Insights lands in the middle: USD 35.66 billion in 2026, growing to USD 91.75 billion by 2035 at 11.07%. Research and Markets projects USD 46.4 billion by 2030 off a 2024 base, at 14.2% annual growth.

Line those up and the spread runs almost two-to-one at comparable points in time. Four firms are drawing the box around the market slightly differently, then running their own growth math inside it. What they do agree on: the direction is up, the size lands somewhere in the tens of billions, and growth runs from high single digits to mid-teens depending on whose model you trust. If you're building a five-year thesis, the gap between an 8.22% CAGR and a 14.60% one compounds into two very different outcomes by year five. Know whose assumptions you're borrowing before you borrow them.

How the market size changes when services and the full care continuum are included

Widen the lens to include hospital services, pediatric care, nutrition, and the full mother-and-child care continuum, and the numbers stop being billions and start being trillions.

Straits Research puts the broader mother-and-child healthcare market at USD 703.24 billion in 2025, headed to USD 2.213 trillion by 2034 at a 13.63% CAGR. The United States alone makes up USD 223.12 billion of that 2025 figure, projected to hit USD 252.73 billion in 2026. That's population size and high per-capita health spending stacked on top of a definition of "maternal and child care" broad enough to include half the health system.

Inside that trillion-dollar number sit smaller, more legible sub-markets. US maternity care specifically comes in at USD 42.1 billion in 2023, growing at a comparatively modest 6.8% CAGR through 2032, the kind of number you'd expect from a segment that's already mature and mostly built out. Postpartum care is smaller still: USD 2.4 billion in 2022, growing at 6.5%. Neither number is going to make headlines next to a trillion-dollar continuum figure. But here's the part that matters for anyone actually building in this space: postpartum and maternity care are where most digital health startups operate. A VC evaluating a postpartum telehealth company weighs the 6.5% growth rate in the USD 2.4 billion slice their portfolio company is actually fighting over — a very different figure from the total mother-and-child continuum hitting USD 2.2 trillion by 2034.

So which number is right? Depends who's asking. A policymaker sizing up national health infrastructure needs the trillion-dollar continuum figure. A product manager pricing a prenatal monitoring device needs the narrow therapeutics number. A VC underwriting a postpartum startup needs the sub-segment figure. Same market, three different rulers, and choosing the wrong one for the pitch deck can undermine the whole argument.

The structural forces driving growth across all scopes

The scope you pick barely changes the picture, because nearly every driver behind the growth shows up across all three.

Start with the basic demographic fact: the number of expectant mothers globally keeps rising, and Asia Pacific carries most of that volume. Layer on top of that a real shift in behavior. Per globalgrowthinsights.com, roughly half (49%) of expecting mothers now go through at least three diagnostic check-ups during pregnancy, a habit that wasn't the default a generation ago and now increasingly is. Rising disposable income in emerging markets is opening up care that used to be out of reach geographically or financially, and government programs aimed at cutting maternal mortality are stacking infrastructure on top of that demand.

The digital and services layer has its own set of accelerants. Telemedicine adoption, which jumped hard during the pandemic and never fully receded, shortened the distance between patients and specialists. Market Research Future points to a rise in consultations with maternal super-specialists as a direct result. Virtual care scaling has also pushed down the cost of delivering postpartum services, and there's a growing appetite for organic and wellness-oriented maternal products, a smaller slice of demand but a real one.

One segment stands out as the fastest grower inside the mother-and-child continuum: fertility services, projected at a 14.12% CAGR per Straits Research. Rising infertility rates, delayed pregnancies, and growing demand for IVF and IUI are doing the heavy lifting, with lifestyle shifts and stress cited as contributing factors.

Here's the part that's genuinely uncomfortable to sit with: some of this growth is downstream of things going wrong. High maternal mortality rates and persistent care gaps are themselves a growth driver, because they open up room for companies that can prove they close those gaps. That's a strange engine for a market to run on. Nobody wakes up rooting for maternal mortality to stay high so a startup's TAM holds up, but that's the mechanism sitting underneath a lot of this funding, and it shapes who gets money later in this piece.

Where the market is concentrated and where growth is fastest geographically

North America owns the biggest slice right now: 35.21% of the mother-and-child healthcare market in 2025, according to Straits Research. High per-capita spending, mature insurance infrastructure, and strong demand for fertility and late-pregnancy services explain most of that share. The region's maternal mortality crisis, which draws plenty of attention in policy circles, doubles as an investment driver here. Care gaps that show up as tragic outcomes in headlines also show up as commercial opportunity for companies that can prove measurable improvement.

Asia Pacific is the one to watch if velocity matters more to you than volume. It's the fastest-growing region at a 15.63% CAGR, per the same Straits Research data, outpacing everyone else. That growth comes from healthcare investment scaling up across India, China, Japan, and Southeast Asia, where even small gains in per-capita spending get multiplied by enormous population bases. A modest percentage gain applied to a much larger population base moves the total by more than a larger percentage gain on a smaller one.

Inside these regional totals, a few patterns repeat. Hospitals dominate care delivery, holding 53.12% of the mother-and-child healthcare market in 2025 per Straits Research, a number that lines up closely with Maximize Market Research's separate estimate of nearly 52% for hospitals within the narrower maternal health market in 2024. Two different scopes landing on nearly the same hospital share is itself a small piece of evidence that hospitals sit structurally at the center no matter how you draw the boundary line. Postnatal services are the largest service-type segment at 35.12% share in 2025, and that matters because postnatal care is exactly where telemedicine and virtual-first startups are fighting hardest for a foothold. The 21-to-30 age bracket is the dominant maternal age segment at 42.34% share, about as close as this market gets to a defined target user for consumer products.

North America is where the institutional money and regulatory scaffolding already exist. Asia Pacific is where the raw growth is arriving fastest, mostly unbuilt. Two different investment theses, pointed at the same underlying market.

How femtech investment flows (and where maternal health sits within it)

Most maternal health startup funding gets counted inside femtech, the broader category covering women's health technology, so the femtech backdrop needs a look before maternal-specific numbers mean anything. That backdrop has had a strange few years.

Femtech peaked at 14.7% of total digital health funding in 2020. By 2024, that share had dropped to 8.5%, with USD 2.2 billion invested globally, according to Galen Growth. Sounds like contraction, and in relative terms it is. The raw dollar figures add a wrinkle worth noting, though: venture funding for women's health startups actually grew 55% in 2024, pulling in somewhere between USD 2.6 billion and USD 3 billion. Femtech is capturing a shrinking slice of a much bigger digital health pie, which is another way of saying digital health overall grew fast enough that even a growing femtech dollar number looks smaller as a share.

Look closer and the money isn't spread evenly at all. Data tracked through newmarketpitch.com found that only 16% of femtech deals in 2024 topped USD 50 million, yet those large rounds captured 66% of total capital. That's a highly skewed distribution for a sector this size. On the other end, Galen Growth found that 71% of femtech startups under six years old hadn't reached Series A yet. Put those two numbers side by side and the pattern is plain: capital isn't spreading across the sector so much as pooling around a small number of proven winners, while a much larger group waits outside.

Zoom out further and the longer arc looks better than the recent dip suggests. Femtech investment has grown substantially over recent years, per Galen Growth, and the category still gets framed as a USD 360 billion opportunity that's historically gone underserved. The most recent data adds a wrinkle worth naming honestly: Silicon Valley Bank tracked USD 2 billion in VC across the US and Europe in 2025, while Dealroom's pure-play femtech tracker shows USD 724 million in 2025 with 2026 on pace for just USD 478 million, an annualized 34% year-over-year drop through mid-2026. Many expect a rebound, but the data doesn't guarantee one on any particular timeline.

The maternal and pregnancy category within femtech: where capital is actually landing

Inside femtech, maternal and pregnancy health ranked second among all femtech categories by funding from 2024 through Q2 2026, pulling in USD 380 million across 26 deals, or 16% of total femtech capital in that window, per New Market Pitch.

The thesis funding this category is fairly blunt: the US maternal mortality crisis has turned outcome measurement into a business model. Companies that can show they improve outcomes are the ones landing health plan partnerships and outcomes-linked contracts. A few actual rounds make that pattern concrete instead of abstract.

Maven Clinic raised a substantial round in 2024, with the money directed toward fertility and maternity care expansion. Pomelo Care raised multiple rounds through 2024 and into 2026, building toward a valuation that placed it among the sector's leading companies. Pomelo's pitch leans hard on outcomes data, citing substantially higher rates of prenatal depression screening and measurable returns on investment for payers. That's one of the clearest examples this market offers of outcomes-linked investor logic in action; the pitch centers on the multiple investors get back, which tells you something about who these pitches are actually written for. Kindbody has raised substantial capital across multiple rounds and reached a valuation placing it among the sector's unicorn-class companies, backed by several prominent institutional investors.

Repeat appearances by the same institutional investors across these deals are not accidental — they signal that certain backers have made sustained bets on the maternal health category as durable rather than a passing trend. When a strategic investor with that kind of reach keeps circling back to the same category, that's a signal the category reads as durable rather than a passing trend.

The valuation math still has a wide gap in it, though. The valuation gap between typical femtech startups and the handful of category leaders is stark, with the top companies reaching multiples of what most others in the sector command. That's the same funding concentration from the femtech section showing up again, just at the level of individual company valuations instead of deal counts.

Philanthropic and government funding as the non-VC layer shaping the market

Venture activity isn't the whole story. Underneath it sits a quieter funding stream, philanthropic and government money, and it's building the infrastructure and outcomes data that make the VC-funded models fundable in the first place.

Merck for Mothers is the clearest example on the philanthropic side, representing a long-running, multi-hundred-million-dollar commitment by a major pharmaceutical company to maternal health equity. Over its run, the program has reached millions of women, with stated goals for continued expansion of that reach. It's a rare case of a major pharmaceutical company treating maternal health as a long-term, outcomes-accountable investment.

Government money is moving too. The CDC made a multi-year investment in 2024 to maternal mortality review committees, exactly the kind of unglamorous data infrastructure that makes outcome measurement possible in the first place. Without it, none of the outcomes-linked commercial models from the last section would have anything to point to. HRSA's Enhancing Maternal Health Initiative launched in January 2024 and now runs across 11 states plus the District of Columbia, expanding the footprint for virtual-first care companies trying to plug into public health systems. The American Hospital Association, meanwhile, has pushed for USD 1 billion for the Title V Maternal and Child Health Block Grant in FY 2025, a sign the pressure to expand public funding isn't letting up.

This layer works alongside venture capital, de-risking it. The data infrastructure the CDC is funding, the state coordination HRSA is building, the equity targets Merck for Mothers is chasing, all of it produces the accountability frameworks that let a company like Pomelo walk into a payer meeting with a 3 to 5x ROI number and have that number mean something to the person across the table.

Reading the investment signals: what the data says about where this market is heading

Look at everything above and one thing is hard to miss: the market size estimates disagree wildly on scope, but not one of them disagrees on direction. Narrow therapeutics, mid-range services, the full trillion-dollar continuum, they're all pointing up, and doing it at a clip that outpaces general economic growth.

What's changed is what gets rewarded within that upward direction. Early femtech funding tended to reward reach: how many users, how many downloads, how many markets entered. The rounds winning capital now center on proof rather than reach, with Pomelo's payer ROI pitch and Maven's value-based care expansion leading that shift. So if 71% of young femtech startups are stuck pre-Series A while 66% of capital goes to a small number of large rounds, what's the actual path across that gap? The data points toward outcomes data as the bridge, and companies that build that case early seem to have a real shot at the funded tier, even while the tier itself stays narrow.

Geography adds its own asymmetry. Asia Pacific's 15.63% growth rate isn't yet matched by an equivalent buildout of private investment infrastructure there, a lag that tends to close as markets mature and local capital formation catches up. That gap hasn't closed yet, and there's no fixed date by which it has to.

The near-term femtech softness, that projected 34% annualized dip through mid-2026 from Dealroom, sits oddly next to a demographic and structural growth story that shows no sign of slowing down. Funding cycles run in cycles; demographic demand, government investment, and payer incentives generally don't. The two aren't in conflict so much as running on different timelines.

For anyone trying to make sense of a headline number, whether it's in a press release or a pitch deck, the useful habit is simple: ask which scope you're looking at before trusting the number, then ask whether the company or program behind it is chasing reach or chasing proof. Those two questions won't tell you exactly where the market lands, but they'll at least tell you whether the number in front of you is measuring the same thing as the one you saw yesterday, which, given how this whole market gets reported, is not a given.